Drug Trial Radar · NCT07308041
A Study to Investigate the Effect of Linaprazan Glurate on the Pharmacokinetics of Amoxicillin
Last checked: Nov 20, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Nov 11, 2025
Primary completion
Dec 22, 2025
Study completion Dec 22, 2025
Sponsor
- Lead sponsor
- Cinclus Pharma Holding ABIndustry
- Sponsor type
- Industry
- First posted
- Dec 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open, single arm, single-center Phase I trial designed to evaluate the effect of seven days repeated oral doses of linaprazan glurate on the pharmacokinetics (PK) of repeated doses of amoxicillin in healthy male and female participants
Conditions
- Drug Interaction
- GERD (Gastroesophageal Reflux Disease)
- Safety, and Tolerability
Interventions
Drug Drug InteractionDrug
The intervention phase consists of 2 periods: in period 1, the pharmacokinetics (PK) of amoxicillin will be evaluated in the absence of linaprazan glurate, in period 2, a potential effect of linaprazan glurate on the PK of amoxicillin will be evaluated as well as the PK of linaprazan glurate following co-administration of amoxicillin.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Characterization of the PK of amoxicillin following a repeated dose before and after repeated administration of linaprazan glurate (AUC)Time frame: Day 1 and Day 8
- Characterization of the PK of amoxicillin following a repeated dose before and after repeated administration of linaprazan glurate (Cmax)Time frame: Day 1 and Day 8
- Characterization of the PK of amoxicillin following a repeated dose before and after repeated administration of linaprazan glurate (Tmax)Time frame: Day 1 and Day 8
- Characterization of the PK of amoxicillin following a repeated dose before and after repeated administration of linaprazan glurate (CL/F)Time frame: Day 1 and Day 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CTC Clinical Trial Consultants AB
Uppsala, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.